Orion published Interim Report January-September 2022 on Thursday, 20 October 2022. The report, related presentation material and webcast recording are available here.
|11/4/2022||Orion Corporation completed share acquisitions|
|11/4/2022||Orion Corporation: Acquisition of Own Shares 04.11.2022|
|11/3/2022||Orion Corporation: Acquisition of Own Shares 03.11.2022|
|11/2/2022||Orion Corporation: Acquisition of Own Shares 02.11.2022|
|10/27/2022||Orion Research Foundation is awarding EUR 1 million in grants and two EUR 100,000 special grants today|
|10/6/2022||Orion publishes Interim Report for January–September 2022 on Thursday 20 October 2022|
|9/5/2022||Orion recalls Devisol Salmiakki dietary supplement from consumers|
|8/8/2022||U.S. FDA approves additional indication of darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)|
The Annual General Meeting of Orion Corporation was held on Wednesday 23 March 2022. The decisions and related material are available here.
The product and service portfolio of Orion includes a variety of human pharmaceuticals, veterinary drugs, APIs and contract manufacturing.
Orion is the largest employer in the Finnish pharmaceutical industry. It is considered to be a good and reliable employer, which is also indicated by its lower-than-average employee turnover.